Scribd Logo
Upload

Welcome to Scribd!

  • Soa I Helfand 12 2 21

    Uploaded by

    Soumabho Das
    19 views4 pages
    BORIM

    Original Title

    soa-i-helfand-12-2-21

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    BORIM

    Copyright:

    © All Rights Reserved
    Download as PDF or read online from Scribd
    Flag for inappropriate content
    19 views4 pages

    Soa I Helfand 12 2 21

    Uploaded by

    Soumabho Das
    BORIM

    Copyright:

    © All Rights Reserved
    Download as PDF or read online from Scribd
    Flag for inappropriate content
    of 4
    COMMONWEALTH OF MASSACHUSETTS: Migdlesex, SS. Board of Registration in Medicine ‘Adjudicatory Case No.2921-047 ) In the Matter of 5 5 IRA HELFAND, MD. ) 3 ‘STATEMENT OF ALLEGATIONS ‘The Board of Registration in Medicine (Board) has determined that good cause exist to believe the following acts occured and constitute a violation for which a licensee may be sanctioned by the Board, The Board therefor alleges that Ia Helfand, M.D., (Respondent) hes practiced medicine in violation ofl, regulations, or good and accepted medical practice as set forth herein, The investigative docket numbers associated with this order to show cause are Docket Nos. 20.490, 19-097, and 19-096, [Biographical Information 1, The Respondent is a 1977 graduate ofthe Alber Binstein College of Medicine snd i board certified in intemal medicine, He has been licensed to practice medicine in Massachusetts since June 18, 1981 under certificate number 47875 and notin any other state ‘Factual Allegations Patient A 2. Omanuary 14,2020 the Respondent fist met Patent A, «shiny five-year old male, fle taking over his care from another provider. During this initial visit Patient A, who appeared “bled up,” acknowledged his use of leit anabolic steroids. Accondingly, the Respondent ordered and obtained Patient A's testosterone level 3. On January 14, 2020 Patient A's testosterone level was 2,872 ng as compared to a normal range of 250-827 ng, Patient A agreed to taper his ict use and follow up with the Respondent in one month, On February 12,2020, Patient self-reported tothe Respondent lapering his iit anabotie steroid use ftom 400 meek to 125 mg/week: 4. On March 25, 2020, Patient A selfseported tothe Respondent he did not taper his ici anabolic steroid use any further than 125 mg/week. On the same day and without any further testosterone level testing, the Respondent presribed Patent A Testosterone CYP 200 imp/ML at 2 mL for total of three (3) rwenty-one (21) day-supplies, as a replacement for the ‘ieily obtained drugs 5, On May 30, 2020 and Angust 19, 2020, the Respondent continued to preseribe Patient A Testosterone CYP 200 mga at mi for thre (3) twenty-one (21) day supplies without further testing of Patient A's testosterone levels, 6. ‘The Respondent's presriptions of testosterone for Patient A on March 15,2020, May 30, 2020, and August 19, 2020 without sequential testosterone level testing did not meet the standard of eve. Patient © 7. OnNovember 19, 2018 the Respondent prescribed Patient Ca twenty-eight (28)

    You might also like